We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

102 hedge funds and large institutions have $113M invested in Neumora Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,635% more call options, than puts

Call options by funds: $1.32M | Put options by funds: $23K

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

50% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 22

22% more capital invested

Capital invested by funds: $92.2M → $113M (+$20.4M)

10% more funds holding

Funds holding: 93 → 102 (+9)

6.37% more ownership

Funds ownership: 31.3% → 37.67% (+6.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
102
Holders Change
+9
Holders Change %
+9.68%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
33
Reduced
22
Closed
12
Calls
$1.32M
Puts
$23K
Net Calls
+$1.3M
Net Calls Change
+$879K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$8.04M
2
SL
Siren LLC
Connecticut
+$4.23M
3
Millennium Management
Millennium Management
New York
+$3.52M
4
IC
Ikarian Capital
Texas
+$2.77M
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.21M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$3.53M
2
TCM
Tang Capital Management
California
-$948K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$780K
4
AQR Capital Management
AQR Capital Management
Connecticut
-$249K
5
SoftBank Group
SoftBank Group
Japan
-$244K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$905K +$1.11M +505,803 New
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$849K -$780K -356,338 -43%
State Street
28
State Street
Massachusetts
$696K – – –
BFM
29
Boothbay Fund Management
New York
$600K +$734K +335,267 New
Federated Hermes
30
Federated Hermes
Pennsylvania
$562K – – –
Cerity Partners
31
Cerity Partners
New York
$492K -$29.3K -13,403 -5%
Morgan Stanley
32
Morgan Stanley
New York
$427K -$79.4K -36,283 -13%
Acadian Asset Management
33
Acadian Asset Management
Massachusetts
$426K -$72.6K -33,173 -12%
Invesco
34
Invesco
Georgia
$407K +$95.9K +43,795 +24%
BCM
35
Bridgeway Capital Management
Texas
$403K – – –
GCM
36
Graham Capital Management
Connecticut
$343K +$75.5K +34,483 +22%
Squarepoint
37
Squarepoint
New York
$333K +$379K +173,061 +1,355%
Northern Trust
38
Northern Trust
Illinois
$332K +$60.3K +27,555 +17%
ECM
39
ExodusPoint Capital Management
New York
$324K +$396K +180,856 New
AH
40
Addis & Hill
Pennsylvania
$292K – – –
ML
41
Maniro Ltd
$283K +$346K +158,231 New
EC
42
EntryPoint Capital
New York
$260K +$318K +145,385 New
OAC
43
OMERS Administration Corp
Ontario, Canada
$246K +$301K +137,300 New
XT
44
XTX Topco
Cayman Islands
$204K +$249K +113,913 New
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$192K +$4.96K +2,267 +2%
RC
46
RBF Capital
California
$188K -$76.3K -34,826 -25%
Bank of America
47
Bank of America
North Carolina
$183K -$76.7K -35,020 -25%
SW
48
SkyOak Wealth
Michigan
$179K – – –
VF
49
Virtu Financial
New York
$174K +$176K +80,189 +466%
UBS Group
50
UBS Group
Switzerland
$170K -$74.8K -34,140 -26%
1
2
3 4 5

NMRA Hedge Fund Activity: Q4 2025 in Review

102 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q4 2025, worth a combined $113M — up 22% from $92.2M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new NMRA positions and 12 closed out — a net gain of 12 holders — while 33 added to existing stakes and 22 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $8.04M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $3.53M sold.

  • 102 institutional investors held Neumora Therapeutics (NMRA) as of Q4 2025, up from 93 in Q3 2025.
  • Funds reported $113M of Neumora Therapeutics stock for Q4 2025, up 22% quarter-over-quarter.
  • 24 funds opened new Neumora Therapeutics positions in Q4 2025 and 12 closed out, a net change of +12 holders.
  • The largest Neumora Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $8.04M added.
  • The largest Neumora Therapeutics seller in Q4 2025 was T. Rowe Price Investment Management, an estimated $3.53M sold.

Based on aggregated 13F filings for Q4 2025.